How Has The DNA And Gene Chip Market Size Evolved Historically?
The dna and gene chip market has seen considerable growth due to a variety of factors.
• The size of the DNA and gene chip market has expanded exponentially in recent times. A surge is expected from $8.19 billion in 2024 to $9.27 billion in 2025, with a compound annual growth rate (CAGR) of 13.1%. Factors contributing to growth in the past include advancements in genomic research, the increasing prominence of personalized medicine, major milestones in the human genome project, developments in drug discovery, and the identification of disease biomarkers.
What Does Future Hold for The DNA And Gene Chip Market Size?
The DNA And Gene Chip market is expected to maintain its strong growth trajectory in upcoming years.
• The market for DNA and gene chips is projected to undergo fast expansion in the upcoming years, with an estimated value of $15.35 billion by 2029, reflecting a compound annual growth rate (CAGR) of 13.4%.
This growth during the forecasted timeframe is ascribed to the progress in precision medicine, proliferation of biomarker discovery, personal therapeutics advancements, applications in cancer research, and a rise in research funding. The forecast period is also expected to showcase trends such as technological advancements, product innovations, the governing regulations and adherence, focus on rare diseases, and a constant decrease in costs.
What Are The Primary Growth Drivers In The DNA And Gene Chip Market?
Increases in the need for early identification of cancer are playing a significant role in driving the growth of the DNA and gene market. Cancer encompasses a wide variety of diseases that occur when abnormal cells proliferate excessively, breach the cellular limits of normal cells, spread to nearby organs, and metastasize to other parts of the body. DNA and gene chips are employed to gauge gene expression patterns, ascertain the genetic and epigenetic composition, and evaluate the genomic regulatory elements that cancer transcription factors bind to in cancerous cells. For example, the American Cancer Society, a community-based voluntary health organization in the US, estimates that 2022 will see about 1.9 million new cancer cases and 609,360 cancer-related deaths in the United States. Consequently, the surging demand for early detection of cancer is fueling the expansion of the DNA and gene chip market.
What Is The Segmentation Of The Global DNA And Gene Chip Market?
The DNA and gene chip market covered in this report is segmented –
1) By Type: Oligonucleotide DNA (o-DNA), Complementary DNA (c-DNA), Other Types
2) By Application: Cancer Diagnostics, Gene Expression, Proteomics, Genomics, Drug Discovery, Agrigenomics, Other Applications
3) By End User: Academic And Government Research Institutes, Biotechnology And Pharmaceutical Companies, Hospitals And Diagnostics Centers, Other End Users
Subsegments:
1) By Oligonucleotide DNA (o-DNA): Custom Oligonucleotide Chips, Commercial Oligonucleotide Arrays
2) By Complementary DNA (c-DNA): cDNA Microarrays, cDNA Expression Arrays
3) By Other Types: Single-Cell RNA Sequencing Chips, SNP (Single Nucleotide Polymorphism) Chips, Whole Genome Amplification Chips
Pre-Book The DNA And Gene Chip Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Emerging Trends Are Shaping The DNA And Gene Chip Market Landscape?
Key trends emerging in the DNA and gene chip market include strategic partnerships and collaboration initiatives between companies. Many organizations in this field are seeking alliances to solidify their standing in the marketplace. To illustrate, Avesthagen Limited, an Indian integrated systems biology platform company, formed a four-year strategic partnership with Wipro Limited, an information technology firm based in India, in June 2022. The alliance enables both firms to carry out a project titled Cancer Risk Assessed by NGS profiling of circulating free DNA and RNA for lung cancer-related genomic sequencing services. Furthermore, Thermo Fisher Scientific, an American analytical instrument supplier, teamed up with the Qatar Genome Program (QGP), a Qatar Foundation (QF) member, to create an Axiom custom genotyping array for pan-Arab populations in May 2022. This array, equipped with 800,000 variants, aims to boost genomic research on conditions like diabetes, cardiovascular diseases, autism, and cancer. Backed by Thermo Fisher's Axiom microarray technology, this venture contributes to Qatar's national vision of improving population's health and advancing precision medicine among people of Arab lineage globally.
Who Are the Key Players In The DNA And Gene Chip Market?
Major companies operating in the DNA and gene chip market include:
• PerkinElmer Inc.
• Illumina Inc.
• Thermo Fisher Scientific Inc.
• Macrogen Inc.
• Agilent Technologies Inc.
• Greiner Bio-One International GmbH
• CapitalBio Corporation
• Microarrays Inc.
• bioMérieux SA
• Applied Microarrays Inc.
• Biometrix Technology Inc.
• Oxford Gene Technology IP Limited
• Bioneer Corporation
• Eurofins MWG Operon LLC
• F. Hoffmann-La Roche Ltd
• QIAGEN N.V.
• Bio-Rad Laboratories Inc.
• BioChain Institute Inc.
• Cepheid
• Eppendorf AG
• Fluidigm Corporation
• GE Healthcare
• Genisphere LLC
• Gyros Protein Technologies AB
• Hitachi High-Technologies Corporation
• LC Sciences
What Are The Regional Insights Into The DNA And Gene Chip Market?
North America was the largest region in the DNA and gene chip market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the DNA and gene chip market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
